Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Extracellular vesicles (EVs) are key players in the pathogenesis of chronic lung diseases, modulating cellular senescence and immune-inflammatory responses. EVs facilitate aberrant intercellular communication, deliver pathogenic miRNAs and proteins, and promote chronic inflammation.
Researchers at Ohio State University are testing psilocybin-assisted therapy to reduce depression and emotional distress in patients with advanced lung cancer. The trial aims to determine whether this approach can address the unique psychological challenges faced by lung cancer patients.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A large Medicare analysis found that depression is associated with higher cancer mortality, while psychotherapy soon after diagnosis reduces cancer risk. Patients with depression had a 21% lower risk of cancer-specific mortality after receiving psychotherapy within four weeks of their diagnosis.
Patients with small cell lung cancer and brain metastases lived 17.4 months with radiosurgery, compared to 8.6 months with whole brain treatment. Radiosurgery was associated with a 40% lower risk of death. The study challenges the long-standing reliance on whole brain treatment for SCLC brain metastases.
A UCLA study found that a dietary supplement, Ca-αKG, reduced lung tumor growth in female mice, but increased tumor growth in male mice. The supplement activated genes associated with better outcomes in women with lung cancer, but had the opposite effect in men.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.
A rare inherited EGFR mutation is associated with a 25-fold increased risk of lung cancer in non-smokers. Carriers of the mutation are more than 60 times as likely to develop lung cancer as people without it.
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
A retrospective study found that consolidative stereotactic radiotherapy improves intracranial control and survival outcomes for patients with EGFR-mutant NSCLC and limited brain metastases. Patients without an intracranial complete response to osimertinib may derive the greatest overall survival benefit from SRT.
The PAPILLON trial demonstrates durable clinical benefit and longest median overall survival reported to date for people with lung cancer carrying an EGFR exon 20 insertion mutation. Amivantamab plus chemotherapy extended overall survival by a clinically meaningful 6 months and cut disease progression risk by 60%.
Patients with class II and class III BRAF alterations in non-small cell lung cancer (NSCLC) have distinct clinicopathologic and genomic characteristics. Class III alterations are associated with worse prognosis and shorter overall survival. STK11, KEAP1, and SMARCA4 co-mutations also linked to worse outcomes.
A Phase 3 trial showed gotistobart significantly improved overall survival, with a 43% reduced risk of death, compared to docetaxel. Higher exposure to gotistobart was associated with improved survival, supporting the selected dosing regimen.
A randomized trial found that brain MRI surveillance alone preserves cognitive function without a difference in survival, supporting MRI surveillance as the standard of care for patients with small cell lung cancer. No apparent difference was observed in overall survival and progression-free survival between the groups.
The IASLC tumor budding-based grading system identified patients with resected lung squamous cell carcinoma at higher risk of poor outcomes and showed potential to guide selection for adjuvant chemotherapy. High-grade tumors were associated with worse overall and disease-free survival.
A mobile CT unit in Northeast Brazil screened 5,223 individuals, identifying 283 with Lung-RADS 3 or 4, and 19 lung cancers were diagnosed. Community health workers played a crucial role in recruiting 894 participants, mostly from rural areas and with lower educational levels.
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
The REZILIENT 3 trial found a six-month improvement in median progression-free survival with the combination of zipalertinib and platinum-pemetrexed chemotherapy. The study showed a 50% reduction in disease progression or death and a substantially higher response rate compared to chemotherapy alone.
The PAPILLON study demonstrates the longest overall survival for patients with EGFR exon 20 insertion-positive advanced NSCLC using first-line amivantamab-chemotherapy. The study found a median overall survival of 34.3 months with amivantamab-chemotherapy versus 27.9 months with chemotherapy.
The Phase 3 DESTINY-Lung04 trial showed that trastuzumab deruxtecan significantly improves progression-free survival in patients with HER2-mutant non-small cell lung cancer, with a median PFS of 14.3 months compared to 8.3 months with pembrolizumab plus chemotherapy. T-DXd also demonstrated a higher objective response rate and better d...
The ARROS-1 trial revealed a 94% objective response rate and 94% nine-month duration-of-response rate among TKI-naive patients with advanced ROS1-positive NSCLC. Intracranial activity was also notable, with a 100% intracranial objective response rate and 78% 12-month intracranial duration-of-response rate.
The eight-year ADAURA update reports a significant overall survival benefit with adjuvant osimertinib in patients with completely resected, EGFR-mutated stage IB-IIIA NSCLC. The study found an eight-year overall survival rate of 74% with osimertinib versus 58% with placebo.
The phase III TAISHAN-302 trial found Tam-Peli to significantly improve overall survival, progression-free survival, and objective response rate in patients with relapsed small-cell lung cancer compared to topotecan. The study also showed a favorable safety profile for Tam-Peli.
A phase 3 trial shows ivonescimab significantly improves overall survival compared to pembrolizumab in patients with PD-L1-positive advanced NSCLC. The median overall survival was 30.8 months with ivonescimab versus 22.6 months with pembrolizumab.
Results from the DeLLphi-309 study suggest that extended-interval dosing regimens of tarlatamab may offer patients greater treatment flexibility while maintaining comparable clinical activity. The study found improved overall survival rates with less frequent dosing schedules, but with similar treatment-emergent adverse event rates.
A Phase III trial found that local consolidative therapy after dual immunotherapy did not improve overall or progression-free survival in patients with metastatic NSCLC. The study tested whether reducing residual tumor burden with radiation or surgery after dual immunotherapy could improve systemic disease control.
The EVOKE-03/KEYNOTE-D46 trial found a numerically longer progression-free survival and higher response rates with sacituzumab govitecan plus pembrolizumab, but no statistically significant benefit in PFS or OS for patients with PD-L1-high metastatic NSCLC
The phase 1b DeLLphi-308 study found that subcutaneous tarlatamab achieved serum exposures comparable to the approved intravenous dosing while maintaining a favorable safety profile, with 30% preliminary objective response rate in patients with ES-SCLC.
The investigational combination of pumitamig and elfetabart drozuntecan demonstrated encouraging early antitumor activity in patients with small cell lung cancer, with a 70.4% overall response rate. The combination also showed a manageable safety profile, supporting further clinical development.
The MAVERICK trial found that MRI surveillance alone significantly improved cognitive failure-free survival by 40% compared to MRI plus PCI in patients with limited-stage and extensive-stage small-cell lung cancer. Serious treatment-related adverse events were also less frequent with MRI surveillance alone.
The Phase III ARTEMIS-008 trial shows that risvutatug rezetecan significantly improves overall survival in patients with relapsed small-cell lung cancer. The treatment reduced the risk of death by 54% and improved progression-free survival and response rates compared to topotecan.
A Phase 1 study showed the investigational therapy demonstrated a manageable safety profile, with 33.3% of patients achieving objective response at the recommended 2.5mg/kg dose. The treatment was well-tolerated, with no treatment-related deaths and only one patient discontinuing due to an adverse event.
The Phase 3 IMpower030 trial found that perioperative atezolizumab plus chemotherapy doubled event-free survival to 62.8 months compared to 34.9 months for chemotherapy alone. The study also showed higher pathological response rates with the atezolizumab regimen.
A new case report describes a 68-year-old woman with stage IV lung adenocarcinoma who developed severe hemolysis after receiving pembrolizumab, despite a negative Coombs test. The patient's hemoglobin declined from 11-12 g/dL to 6.4 g/dL, and laboratory markers of hemolysis improved with corticosteroid treatment. The case highlights th...
Research reveals the human microbiome's role in lung cancer immunotherapy, with specific bacterial species and metabolites showing promise as next-generation biomarkers. Higher oral microbial diversity and certain bacteria like AKK are associated with better outcomes, while others predict poorer outcomes.
A new class of protein-based MRI contrast agent detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches. The technology targets collagen type I, a structural protein found at elevated levels in aggressive lung tumors and metastatic lesions.
Researchers found that patients with lung cancer had more detectable microplastics and higher microplastic burdens in their lung wash and tissue samples. The study suggests a link between microplastics and lung disease, with polypropylene and polyethylene being the most common types of plastic.
Research reveals UBE2M's critical regulatory link to inflammation and innate immune pathway in KrasG12D driven non-small cell lung cancer. Simultaneous UBE2M deletion and KrasG12D activation causes severe inflammatory TME, shortening life-span and promoting tumor growth.
A real-world observational study found no significant survival benefit from post-surgery immunotherapy in NSCLC patients with pathological complete response after neoadjuvant chemoimmunotherapy. The study suggests that these patients may already derive the maximum benefit from neoadjuvant therapy alone.
Daraxonrasib demonstrated durable responses in pretreated patients with RAS-mutant non-small cell lung cancer, with an objective response rate of 42% and median progression-free survival of 8.3 months. The therapy's safety profile, while notable, is considered manageable compared to chemotherapy options.
Researchers at Columbia University have discovered a new type of cell that protects lung cancers from attacks by the immune system. The new cells, called CHL1 fibroblasts, promote lung cancer by recruiting regulatory T cells to the border of the tumor.
Researchers found that radiation to the thymus during NSCLC treatment increased cancer spread and mortality risk in patients with relatively healthy thymus. Thymic health scores were associated with T-cell diversity, longevity, and cancer outcomes.
A new preclinical study shows that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. The combination therapy induces irreparable DNA damage in cancer cells and stimulates the immune system to combat the disease.
Sylvester Cancer Center has ranked #1 in Florida and #23 nationwide, thanks to discoveries of a genetic mutation that enables blood cancers to evade BTK inhibitors. Researchers are exploring new therapies and using AI to advance precision medicine.
A UC study found that only 15% of eligible American adults discuss lung cancer screenings with their doctors, highlighting the need for increased awareness and education about the lifesaving procedure. The study suggests that stigma and fear around lung cancer, as well as lack of information about the low-dose CT scan, may be barriers ...
The PolyU research team has developed TRUECAM, an integrated AI framework that ensures data and model trustworthiness in cancer diagnosis. The framework can assess the level of an AI's confidence in its diagnostic outputs and proactively prompts pathologists to review cases when uncertainty is high.
A large international study suggests that age may influence lung cancer biology and could help guide more personalized treatment strategies. Younger adults with non-small cell lung cancer are significantly more likely to have genetic alterations that can be matched with targeted therapies.
Multi-source data-driven machine learning is transforming lung cancer diagnosis, treatment, and prognosis by analyzing complex medical data. The review highlights the innovative applications of this technology in early screening, personalized treatment optimization, and dynamic prognostic risk stratification.
MIT researchers found that inhibiting caspase-1, an enzyme involved in lung inflammation, reduces the risk of developing tumors. The drug has already gone into clinical trials for other diseases and may be tested as a preventative measure for people at high risk for lung cancer.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
A recent study covering 46 countries found that smokers are largely unaware of the cardiovascular risks associated with smoking and second-hand smoke. This knowledge gap is particularly concerning given the high number of cardiovascular deaths worldwide linked to tobacco use.
Researchers found molecular signs of changes in the blood of people exposed to air pollution, detectable years before diagnosis with lung cancer. The study suggests potential biomarkers for early detection and prevention strategies.
Researchers developed a simple, fast, and low-cost blood test that identifies the tumor's biological fingerprint with over 90% accuracy. The test distinguishes between lung cancer patients and healthy individuals without DNA sequencing.
A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...
ASTRA-Net helps reconstruct overlooked peripheral airways, creating more complete maps for bronchoscopy procedures. The AI framework demonstrates strong performance in identifying fine peripheral airways and supports navigation to difficult-to-reach lung lesions.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A blood test that detects circulating tumor DNA can predict whether patients with advanced non-small cell lung cancer are benefiting from immunotherapy. The test was found to be accurate in predicting therapy response and can provide clinically meaningful information weeks before conventional imaging.
Researchers found that high brain metabolism is associated with longer overall survival, and it's an independent prognostic factor for overall survival. Brain metabolism measured by ¹⁸F-FDG PET/CT provides valuable insight into patient outcomes and may help identify patients most likely to benefit from early supportive care.